Leaflet HYDREA 500mg capsules


Indicated for: myeloproliferative neoplasms; sickle cell disease

Substance: hydroxycarbamide (antineoplastic agent)

ATC: L01XX05 (Antineoplastic and immunomodulating agents | Other antineoplastic agents)

Hydroxyurea is a medication used to treat certain types of cancer, such as chronic myeloid leukemia, and other conditions like sickle cell anemia. It works by inhibiting DNA synthesis, which slows the growth of cancerous or abnormal cells.

The medication is taken orally, as directed by a doctor.

Side effects may include nausea, vomiting, decreased blood cell counts, fatigue, or skin rashes. In rare cases, severe allergic reactions or hematologic toxicity may occur.

Patients should be closely monitored during treatment and inform their doctor about any other medications they are taking. Pregnant or breastfeeding women should not use this medication.

General data about HYDREA 500mg

  • Substance: hydroxycarbamide
  • Date of last drug list: 01-05-2026
  • Commercial code: W03542001
  • Concentration: 500mg
  • Pharmaceutical form: capsules
  • Quantity: 100
  • Product type: original
  • Price: 121.69 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: CORDEN PHARMA LATINA S.p.A. - ITALIA
  • Holder: BRISTOL MYERS SQUIBB KFT - UNGARIA
  • Number: 11474/2019/01
  • Shelf life: 3 years

Pharmaceutical forms available for hydroxycarbamide

Concentrations available for hydroxycarbamide

  • 1000mg
  • 500mg

Compensation lists for HYDREA 500mg Bristol Myers Squibb

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

121.69 RON

121.69 RON

0.00 RON